Precigen, Inc. (PGEN) Q4 2025 Earnings Call March 25, 2026 4:30 PM EDT
Company Participants
Steven Harasym – VP & Head of Investor Relations
Helen Sabzevari – President, CEO & Director
Phil Tennant – Chief Commercial Officer
Harry Thomasian – Chief Financial Officer
Rutul Shah – Chief Operating Officer
Conference Call Participants
Jason Butler – Citizens JMP Securities, LLC, Research Division
Swayampakula Ramakanth – H.C. Wainwright & Co, LLC, Research Division
Brian Cheng
Michael DiFiore – Evercore ISI Institutional Equities, Research Division
Presentation
Operator
Good afternoon, ladies and gentlemen, and welcome to the Precigen Full Year 2025 Financial Results and Business Updates Conference Call. [Operator Instructions] This call is recorded on Wednesday, March 25, 2026.
I would now like to turn the conference over to Steve Harasym. Please go ahead.
Steven Harasym
VP & Head of Investor Relations
Thank you, operator, and thank you to all those joining us for our Fourth Quarter and Year-end 2025 Update Call. Joining me today are Helen Sabzevari, our President and CEO; Phil Tennant, our Chief Commercial Officer; and Harry Thomasian, our CFO.
Before we begin our prepared remarks, I remind everyone that we will be making certain forward-looking statements. These statements are based on our current expectations and beliefs. We encourage you to review the slide in the presentation and in our SEC filings, which include risks and uncertainties that could cause actual results to differ from today’s forward-looking statements.
With that, I will now turn the call over to Helen.
Helen Sabzevari
President, CEO & Director
Thank you, Steve. I would like to extend a warm welcome to all those joining us for our update call today. In the short time since the early and full approval of PAPZIMEOS in August, the standard of care first-line treatment for adult RRP, we are seeing a tremendous progress with the first-ever therapeutic commercial launch
Read the full article here